SCHEMBL17796415

SCHEMBL17796415

Cc1cc(Cl)ncc1C(=O)N1CCC(C)(O)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.41
▸ MTOR P42345 2/20 0.41
▸ RAB9A P51151 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ VNN1 O95497 1/20 0.39
▸ GRM3 Q14832 1/20 0.39
▸ PAK4 O96013 1/20 0.39
▸ L3MBTL3 Q96JM7 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ PSEN1 P49768 1/20 0.38
▸ PSEN2 P49810 1/20 0.38
▸ APH1B Q8WW43 1/20 0.38
▸ NCSTN Q92542 1/20 0.38
▸ APH1A Q96BI3 1/20 0.38
▸ PSENEN Q9NZ42 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ CYP46A1 Q9Y6A2 3/20 0.37
▸ PKLR P30613 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17804187 0.83 HPGD (0.48) RAB9AALDH1A1L3MBTL3L3MBTL1KMT2A
SCHEMBL17796530 0.81 HPGD (0.56) —
SCHEMBL17796521 0.75 RAB9A (0.44) PIK3CAMTORRAB9AALDH1A1L3MBTL3
SCHEMBL17796420 0.75 RAB9A (0.44) PIK3CAMTORRAB9AALDH1A1L3MBTL3
SCHEMBL17796675 0.73 KMT2A (0.48) PIK3CAMTORALDH1A1GRM3RORC
SCHEMBL17796440 0.73 KMT2A (0.48) PIK3CAMTORALDH1A1GRM3RORC
SCHEMBL15547132 0.70 GABRP (0.44) RAB9AALDH1A1
SCHEMBL15713423 0.69 KCNQ3 (0.43) RAB9AALDH1A1L3MBTL1
SCHEMBL3752864 0.69 GABRP (0.61) RAB9AALDH1A1KMT2A
SCHEMBL30414922 0.69 KCNQ3 (0.43) RAB9AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 — — US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 — — EP disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA PIK3CA 2494/4885MTOR 625/4885RAB9A 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback